News

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
BioPharma Dive21h
As gene therapy sales sputter, one biotech aims to defy the odds
With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial ...
Zacks Small Cap Research on MSN4d
ARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Countdown Begins to November 18, 2025 PDUFA for Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is developing plozasiran for the ...
ACA premiums set to spike
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story ACA premiums set to spike People who buy ...